Hub : Traits :

Schizophrenia (2014)

623 significantly associated models · 165 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	7715776	9571422	2	1	1.9e-08	2.1e-07	7.8e-01	100	RERE
2	1	149880483	150316576	1	1	9.2e-08	1.1e-08	4.2e-02	87	PLEKHO1
3	1	242590540	244359621	3	2	1.8e-10	1.0e-07	1.9e-01	94	CEP170 SDCCAG8
4	2	73631564	74155641	1	1	2.8e-07	1.8e-07	2.2e-01	94	ALMS1P
5	2	197134790	202078494	11	2	2.1e-13	1.1e-11	8.5e-01	100	C2orf47 SF3B1
6	2	233047291	234434621	4	2	8.7e-11	1.2e-13	1.4e-02	89	NGEF
7	3	1442951	3792945	1	1	2.0e-07	3.9e-09	3.1e-04	62	CNTN4
8	3	36235084	37614424	1	1	1.3e-07	5.7e-10	5.7e-04	69	AC011816.1
9	3	51616334	53778875	15	1	4.1e-11	6.3e-10	2.3e-01	96	ITIH4-AS1
10	3	63121945	64546545	1	1	9.1e-10	1.5e-09	1.0e+00	100	THOC7
11	3	135273949	137261517	5	1	1.6e-10	3.4e-11	4.7e-03	82	PCCB
12	3	179627093	181023400	1	1	2.7e-07	2.9e-10	8.3e-05	61	TTC14
13	4	169845720	171339965	1	1	3.7e-08	3.7e-08	1.0e+00	100	CLCN3
14	5	59474215	60936935	1	1	2.0e-10	1.8e-11	2.2e-03	79	ERCC8
15	5	136972187	138474788	2	1	3.9e-11	2.8e-08	1.8e-02	82	FAM53C
16	5	138860604	140337279	1	1	9.3e-08	3.8e-06	3.6e-06	0	CYSTM1
17	6	24300846	24913126	2	1	4.6e-12	3.2e-06	3.0e-01	95	KIAA0319
18	6	43034850	43582584	1	1	2.0e-07	5.3e-07	1.0e+00	100	ZNF318
19	6	84017921	84666980	1	1	1.1e-07	6.9e-08	1.9e-01	94	SNAP91
20	7	1161158	2977732	2	1	4.8e-09	9.4e-13	8.6e-06	61	MAD1L1
21	7	99591418	100979310	1	1	1.2e-07	1.3e-06	3.8e-01	97	GIGYF1
22	7	109603832	111895681	2	1	7.4e-11	4.0e-12	1.1e-03	78	IMMP2L
23	8	8092025	8349757	1	1	1.4e-07	3.2e-07	5.7e-01	99	FLJ10661
24	8	9646560	11045161	1	1	3.1e-07	2.9e-07	6.7e-04	56	RP11-981G7.6
25	8	16409107	17851248	1	1	2.5e-07	3.1e-09	3.9e-04	64	VPS37A
26	8	142839492	144323692	1	1	6.6e-09	7.9e-12	4.1e-07	45	BAI1
27	10	103313599	105647095	12	1	5.3e-17	4.7e-15	4.1e-03	87	AS3MT
28	11	45945837	47632707	4	1	1.4e-09	6.9e-10	3.0e-02	88	ATG13
29	11	63316786	64707978	1	1	3.3e-09	2.1e-05	8.6e-01	100	PPP1R14B
30	12	1204676	2805632	2	1	4.7e-14	1.2e-17	5.3e-05	78	CACNA2D4
31	12	110175537	111634281	2	1	1.7e-08	3.8e-09	4.5e-02	88	VPS29
32	12	122713991	124591385	9	1	1.7e-11	1.7e-11	1.9e-02	88	PITPNM2
33	14	70676661	72273020	1	1	1.8e-09	2.0e-08	9.1e-01	100	PCNX
34	14	103161201	105211221	12	1	3.8e-12	4.9e-12	2.3e-01	97	KLC1
35	15	78135979	79537269	2	1	7.6e-09	3.7e-09	1.0e+00	100	CHRNA5
36	15	83167559	84013521	1	1	3.2e-08	1.2e-07	8.2e-01	100	CPEB1
37	15	84151637	85895721	9	1	1.1e-09	1.7e-08	8.1e-01	100	AC103965.1
38	15	90718541	92135418	2	1	1.7e-13	5.4e-11	8.4e-01	100	FES
39	16	28825605	30823047	7	1	1.3e-08	3.1e-08	6.0e-01	99	MAPK3
40	16	88946761	90172696	2	1	1.6e-08	1.8e-07	4.9e-03	71	CPNE7
41	17	1717695	2453908	1	1	6.9e-08	9.5e-09	2.4e-02	85	SMG6
42	17	17017584	18325085	5	1	1.9e-08	2.6e-08	3.6e-01	97	LRRC48
43	19	18408222	20432930	9	2	1.2e-09	3.1e-09	8.8e-02	92	GMIP SUGP2
44	22	39192995	43232818	13	3	2.1e-10	1.6e-10	2.4e-03	77	MGAT3 NAGA XPNPEP3

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Schizophrenia (2018)	14.7	48	30	66.7	1.00	9.5e-50	AC011816.1 AC103965.1 ALMS1P AS3MT ATG13 BAI1 C2orf47 CACNA2D4 CEP170 CHRNA5 CLCN3 CNTN4 CPEB1 CPNE7 CYSTM1 ERCC8 FAM53C FES FLJ10661 GIGYF1 GMIP IMMP2L ITIH4-AS1 KIAA0319 KLC1 LRRC48 MAD1L1 MAPK3 MGAT3 NAGA NGEF PCCB PCNX PITPNM2 PLEKHO1 PPP1R14B RERE RP11-981G7.6 SDCCAG8 SF3B1 SMG6 SNAP91 SUGP2 THOC7 TTC14 VPS29 XPNPEP3 ZNF318
Bipolar Disorder or Schizophrenia	14.6	47	33	73.3	0.99	4.3e-39	AC011816.1 AC103965.1 ALMS1P AS3MT ATG13 BAI1 C2orf47 CACNA2D4 CEP170 CHRNA5 CLCN3 CNTN4 CPEB1 CPNE7 CYSTM1 ERCC8 FAM53C FES FLJ10661 GIGYF1 GMIP IMMP2L ITIH4-AS1 KIAA0319 KLC1 LRRC48 MAD1L1 MAPK3 MGAT3 NAGA NGEF PCCB PCNX PITPNM2 PLEKHO1 PPP1R14B RERE RP11-981G7.6 SDCCAG8 SF3B1 SNAP91 SUGP2 THOC7 TTC14 VPS37A XPNPEP3 ZNF318
Bipolar Disorder (2018)	5.7	8	3	6.7	0.99	5.6e-07	AC103965.1 CACNA2D4 ITIH4-AS1 PLEKHO1 PPP1R14B SNAP91 SUGP2 XPNPEP3
Bipolar Disorder (2011)	5.1	3	0	0.0	0.00	1.0e+00	CACNA2D4 ITIH4-AS1 SNAP91
Pack years adult smoking proportion	4.9	2	1	2.2	0.00	1.0e+00	CHRNA5 KLC1
Pack years of smoking	4.4	1	1	2.2	0.00	1.0e+00	CHRNA5
Diastolic blood pressure, automated reading	4.1	10	8	17.8	-0.14	6.9e-01	ALMS1P CEP170 FES FLJ10661 GIGYF1 NAGA PITPNM2 RERE RP11-981G7.6 SDCCAG8
Worrier / anxious feelings	3.9	7	5	11.1	0.39	3.9e-01	AS3MT C2orf47 CACNA2D4 FLJ10661 ITIH4-AS1 PCCB RP11-981G7.6
Impedance of whole body	3.7	13	10	22.2	0.43	1.4e-01	AC103965.1 AS3MT CACNA2D4 ERCC8 FLJ10661 ITIH4-AS1 MAPK3 RERE RP11-981G7.6 SF3B1 SMG6 SUGP2 VPS29
Impedance of leg (right)	3.6	15	10	22.2	0.19	5.0e-01	AC103965.1 AS3MT C2orf47 ERCC8 FES FLJ10661 ITIH4-AS1 KLC1 LRRC48 MAPK3 NGEF RP11-981G7.6 SF3B1 SMG6 SUGP2
Impedance of leg (left)	3.6	13	10	22.2	0.17	5.7e-01	AC103965.1 AS3MT ERCC8 FES FLJ10661 ITIH4-AS1 LRRC48 MAPK3 NGEF RP11-981G7.6 SF3B1 SMG6 SUGP2
Vascular/heart problems diagnosed by doctor	3.6	8	1	2.2	0.37	3.7e-01	AS3MT FES FLJ10661 PCCB PCNX PPP1R14B RP11-981G7.6 SMG6
Schizophrenia vs Biploar Disorder	3.5	2	0	0.0	0.00	1.0e+00	ATG13 VPS29
Heel bone mineral density (BMD) T-score, automated (left)	3.4	5	4	8.9	0.16	8.0e-01	FLJ10661 NGEF RERE RP11-981G7.6 SMG6
High blood pressure	3.4	7	3	6.7	-0.53	2.3e-01	FES FLJ10661 PCCB PCNX RP11-981G7.6 SDCCAG8 SMG6
Nervous feelings	3.4	6	5	11.1	0.42	4.0e-01	AS3MT FLJ10661 ITIH4-AS1 MAPK3 PCCB RP11-981G7.6
Pulse rate, automated reading	3.4	5	2	4.4	0.81	9.4e-02	AC103965.1 GIGYF1 ITIH4-AS1 LRRC48 VPS29
Hypertension (Self-reported)	3.4	6	3	6.7	-0.48	3.3e-01	FES FLJ10661 PCCB PPP1R14B RP11-981G7.6 SMG6
Heel bone mineral density (BMD) T-score, automated (right)	3.3	6	4	8.9	0.06	9.1e-01	FLJ10661 KIAA0319 NGEF RERE RP11-981G7.6 SMG6
Impedance of arm (right)	3.3	12	7	15.6	0.39	2.1e-01	AC103965.1 ERCC8 FAM53C FLJ10661 ITIH4-AS1 MAPK3 RP11-981G7.6 SF3B1 SMG6 SNAP91 SUGP2 VPS29
Risk taking	3.3	3	1	2.2	0.00	1.0e+00	CEP170 KLC1 PCCB
Systolic blood pressure, automated reading	3.2	6	5	11.1	0.27	6.1e-01	AS3MT FES FLJ10661 PPP1R14B RERE RP11-981G7.6
Impedance of arm (left)	3.2	13	7	15.6	0.34	2.5e-01	AC103965.1 AS3MT ERCC8 FLJ10661 ITIH4-AS1 MAPK3 NAGA RP11-981G7.6 SF3B1 SMG6 SNAP91 SUGP2 VPS29
Worry (Nagel 2018)	3.1	8	3	6.7	0.99	7.4e-06	AS3MT C2orf47 ITIH4-AS1 MAPK3 PCCB SUGP2 THOC7 XPNPEP3
Heel T-Score	3.0	10	7	15.6	-0.06	8.6e-01	AC103965.1 ALMS1P ATG13 KLC1 MAPK3 NGEF PITPNM2 PLEKHO1 RERE SMG6
Systolic Blood Pressure	3.0	10	6	13.3	0.07	8.4e-01	AS3MT C2orf47 FES LRRC48 PCNX PPP1R14B RERE SDCCAG8 TTC14 VPS29
High blood pressure (mother)	3.0	1	1	2.2	0.00	1.0e+00	FES
Pulse rate	2.9	3	1	2.2	0.00	1.0e+00	GIGYF1 ITIH4-AS1 LRRC48
Reaction Time	2.8	6	0	0.0	1.00	2.5e-06	ATG13 C2orf47 IMMP2L NGEF RERE SNAP91
Neuroticism score	2.8	3	3	6.7	0.00	1.0e+00	FLJ10661 PCCB RP11-981G7.6
Mean time to correctly identify matches	2.8	4	0	0.0	1.00	6.7e-04	ATG13 IMMP2L RERE SNAP91
Verbal and Numeric Reasoning (VNR)	2.7	4	1	2.2	-0.99	1.2e-02	ALMS1P ITIH4-AS1 MGAT3 NAGA
Smoking Status	2.7	6	1	2.2	-0.29	5.8e-01	AS3MT ERCC8 FES KLC1 RERE SNAP91
Cardiovascular Disease	2.7	7	3	6.7	-0.32	4.9e-01	AS3MT ATG13 FES KLC1 PCCB PCNX SDCCAG8
Number of incorrect matches in round	2.7	3	1	2.2	0.00	1.0e+00	AS3MT FES MAPK3
Tense / 'highly strung'	2.7	5	1	2.2	0.22	7.2e-01	CACNA2D4 FLJ10661 MAPK3 PCCB RERE
Medication: Blood pressure	2.7	1	1	2.2	0.00	1.0e+00	FES
Irritability	2.7	2	2	4.4	0.00	1.0e+00	FLJ10661 RP11-981G7.6
Medication: Blood pressure	2.6	3	1	2.2	0.00	1.0e+00	CPNE7 FES RP11-981G7.6
Intelligence (Savage-Jansen 2018)	2.5	8	2	4.4	-0.30	4.7e-01	ALMS1P IMMP2L ITIH4-AS1 KLC1 MGAT3 NAGA NGEF PITPNM2
Fed-up feelings	2.5	2	1	2.2	0.00	1.0e+00	FLJ10661 PCCB
Body mass index (BMI)	2.5	10	4	8.9	-0.40	2.6e-01	AS3MT BAI1 C2orf47 FLJ10661 ITIH4-AS1 KLC1 MAPK3 RP11-981G7.6 SMG6 VPS29
Medication for cholesterol, blood pressure or diabetes	2.5	1	1	2.2	0.00	1.0e+00	FES
Arm fat-free mass (right)	2.5	11	8	17.8	-0.43	1.9e-01	AS3MT ERCC8 FAM53C FLJ10661 MAPK3 MGAT3 NGEF PITPNM2 SF3B1 SMG6 VPS29
Arm predicted mass (right)	2.5	11	7	15.6	-0.42	1.9e-01	AS3MT ERCC8 FAM53C FLJ10661 MAPK3 MGAT3 NGEF PITPNM2 SF3B1 SMG6 VPS29
Illnesses of father: High blood pressure	2.5	1	1	2.2	0.00	1.0e+00	FES
Arm fat-free mass (left)	2.5	10	6	13.3	-0.41	2.3e-01	AS3MT ERCC8 FLJ10661 MAPK3 MGAT3 NGEF PITPNM2 SF3B1 SMG6 VPS29
Arm predicted mass (left)	2.5	10	5	11.1	-0.43	2.2e-01	AS3MT ERCC8 FLJ10661 MAPK3 MGAT3 NGEF PITPNM2 SF3B1 SMG6 VPS29
Tanning	2.4	3	1	2.2	0.00	1.0e+00	CPNE7 ERCC8 ITIH4-AS1
Leg fat-free mass (left)	2.4	12	6	13.3	-0.33	3.0e-01	AS3MT C2orf47 CEP170 ERCC8 FES FLJ10661 MAPK3 MGAT3 NGEF PITPNM2 SMG6 VPS29
Current tobacco smoking	2.4	4	0	0.0	0.42	5.8e-01	AS3MT CHRNA5 KLC1 RP11-981G7.6
Chronic bronchitis/emphysema (father)	2.4	1	1	2.2	0.00	1.0e+00	CHRNA5
Leg predicted mass (left)	2.4	12	6	13.3	-0.33	2.9e-01	AS3MT C2orf47 CEP170 ERCC8 FES FLJ10661 MAPK3 MGAT3 NGEF PITPNM2 SMG6 VPS29
Mouth/teeth dental problems: Dentures	2.4	2	0	0.0	0.00	1.0e+00	CHRNA5 FLJ10661
Suffer from 'nerves'	2.4	2	1	2.2	0.00	1.0e+00	AS3MT FLJ10661
Whole body fat-free mass	2.4	11	6	13.3	-0.40	2.2e-01	AS3MT CEP170 ERCC8 FLJ10661 MAPK3 MGAT3 NGEF PITPNM2 SF3B1 SMG6 VPS29
Leg fat-free mass (right)	2.4	12	6	13.3	-0.33	2.9e-01	AS3MT C2orf47 CEP170 ERCC8 FES FLJ10661 MAPK3 MGAT3 NGEF PITPNM2 SMG6 VPS29
Whole body water mass	2.4	11	7	15.6	-0.40	2.2e-01	AS3MT CEP170 ERCC8 FLJ10661 MAPK3 MGAT3 NGEF PITPNM2 SF3B1 SMG6 VPS29
Leg predicted mass (right)	2.4	12	6	13.3	-0.33	3.0e-01	AS3MT C2orf47 CEP170 ERCC8 FES FLJ10661 MAPK3 MGAT3 NGEF PITPNM2 SMG6 VPS29
Basal metabolic rate	2.4	12	5	11.1	-0.46	1.3e-01	AS3MT C2orf47 CEP170 ERCC8 FLJ10661 MAPK3 MGAT3 NGEF PITPNM2 SF3B1 SMG6 VPS29
Neuroticism (2016)	2.3	3	1	2.2	0.00	1.0e+00	FLJ10661 RP11-981G7.6 THOC7
BMI	2.3	10	6	13.3	-0.60	6.6e-02	AS3MT BAI1 C2orf47 CPNE7 ITIH4-AS1 KLC1 MAPK3 SMG6 TTC14 VPS29
Allergy or Eczema	2.3	4	2	4.4	-0.31	6.9e-01	LRRC48 PITPNM2 RERE SF3B1
Sensitivity / hurt feelings	2.3	3	2	4.4	0.00	1.0e+00	FES FLJ10661 SUGP2
Maternal smoking around birth	2.3	3	1	2.2	0.00	1.0e+00	AS3MT CHRNA5 KLC1
Weight	2.3	9	3	6.7	-0.49	1.8e-01	AC103965.1 AS3MT C2orf47 FLJ10661 MAPK3 NGEF PITPNM2 SMG6 VPS29
Trunk fat-free mass	2.3	11	7	15.6	-0.37	2.6e-01	AS3MT ERCC8 FAM53C MAPK3 MGAT3 NAGA NGEF PITPNM2 SF3B1 SMG6 VPS29
Hip circumference	2.3	9	3	6.7	-0.59	9.3e-02	AC103965.1 AS3MT BAI1 ERCC8 FLJ10661 ITIH4-AS1 MAPK3 PITPNM2 VPS29
Trunk predicted mass	2.3	11	7	15.6	-0.37	2.6e-01	AS3MT ERCC8 FAM53C MAPK3 MGAT3 NAGA NGEF PITPNM2 SF3B1 SMG6 VPS29
Comparative body size at age 10	2.3	6	2	4.4	-0.65	1.6e-01	ERCC8 FLJ10661 MAPK3 SMG6 SUGP2 VPS37A
Smoking status: Current	2.3	2	0	0.0	0.00	1.0e+00	AS3MT KLC1
Neuroticism (Nagel 2018)	2.2	4	1	2.2	0.73	2.7e-01	AS3MT PCCB RERE SUGP2
Waist Hip Ratio (WHR)	2.2	11	5	11.1	0.12	7.4e-01	AC103965.1 ERCC8 FAM53C ITIH4-AS1 LRRC48 MGAT3 PCCB PCNX PITPNM2 SF3B1 SMG6
Medication: Atenolol	2.2	1	1	2.2	0.00	1.0e+00	FES
Waist circumference	2.2	6	1	2.2	-0.88	1.9e-02	AS3MT BAI1 C2orf47 MAPK3 PCCB SMG6
Past tobacco smoking	2.2	1	1	2.2	0.00	1.0e+00	AS3MT
Fluid intelligence score	2.2	3	1	2.2	0.00	1.0e+00	ALMS1P MGAT3 PITPNM2
Father's age at death	2.2	2	2	4.4	0.00	1.0e+00	CHRNA5 FES
Qualifications: A levels/AS levels or equivalent	2.2	4	1	2.2	-0.36	6.4e-01	ALMS1P ERCC8 MGAT3 PITPNM2
Medication: Paracetamol	2.2	1	0	0.0	0.00	1.0e+00	SDCCAG8
Headache pain in last month	2.2	2	2	4.4	0.00	1.0e+00	CEP170 SDCCAG8
Qualifications: College or University degree	2.2	7	4	8.9	0.10	8.3e-01	ALMS1P CEP170 ERCC8 KLC1 MGAT3 NGEF PITPNM2
Illnesses of father: Heart disease	2.2	2	2	4.4	0.00	1.0e+00	FES SMG6
Illnesses of father: None of the above (group 1)	2.2	1	1	2.2	0.00	1.0e+00	FES
Arm fat mass (left)	2.2	8	3	6.7	-0.41	3.1e-01	AS3MT BAI1 C2orf47 CPNE7 FLJ10661 KLC1 MAPK3 VPS29
Guilty feelings	2.2	2	0	0.0	0.00	1.0e+00	FLJ10661 KIAA0319
Arm fat mass (right)	2.1	8	2	4.4	-0.39	3.4e-01	AS3MT BAI1 C2orf47 CPNE7 FLJ10661 KLC1 MAPK3 VPS29
Miserableness	2.1	3	1	2.2	0.00	1.0e+00	CEP170 FLJ10661 RP11-981G7.6
Medication: Bendroflumethiazide	2.1	3	1	2.2	0.00	1.0e+00	FES FLJ10661 RP11-981G7.6
Ever smoked	2.1	1	0	0.0	0.00	1.0e+00	AS3MT
Leg fat mass (left)	2.1	6	3	6.7	-0.78	6.6e-02	AS3MT C2orf47 FLJ10661 ITIH4-AS1 MAPK3 VPS29
Breast Cancer	2.0	3	1	2.2	0.00	1.0e+00	FES LRRC48 SUGP2
Stomach or abdominal pain in last month	2.0	1	0	0.0	0.00	1.0e+00	GIGYF1
Frequency of tenseness / restlessness in last 2 weeks	2.0	1	0	0.0	0.00	1.0e+00	PCCB
Heart attack	2.0	1	1	2.2	0.00	1.0e+00	FES
Lung cancer (father)	2.0	1	1	2.2	0.00	1.0e+00	CHRNA5
Worry too long after embarrassment	2.0	2	2	4.4	0.00	1.0e+00	FLJ10661 PCCB
Whole body fat mass	2.0	5	3	6.7	-0.74	1.5e-01	AC103965.1 AS3MT C2orf47 FLJ10661 MAPK3
Leg fat mass (right)	2.0	7	3	6.7	-0.50	2.5e-01	AC103965.1 AS3MT FLJ10661 ITIH4-AS1 MAPK3 RP11-981G7.6 VPS29
Unable to work because of sickness or disability	2.0	1	0	0.0	0.00	1.0e+00	SF3B1
Coronary Artery Disease (CAD)	1.9	3	0	0.0	0.00	1.0e+00	AS3MT LRRC48 SMG6
Lung FEV1/FVC ratio	1.9	7	3	6.7	-0.12	7.9e-01	AC103965.1 CHRNA5 ITIH4-AS1 LRRC48 MAPK3 RERE SMG6
Neuroticism	1.9	3	2	4.4	0.00	1.0e+00	AS3MT PCCB RERE
Hayfever, allergic rhinitis or eczema	1.9	3	2	4.4	0.00	1.0e+00	PITPNM2 RERE SF3B1
Sitting height	1.9	7	3	6.7	0.19	6.6e-01	AC103965.1 FAM53C MGAT3 NGEF PITPNM2 SUGP2 THOC7
Trunk fat mass	1.9	5	3	6.7	-0.78	1.2e-01	AC103965.1 AS3MT C2orf47 CPNE7 MAPK3
Hearing difficulty/problems with background noise	1.9	3	0	0.0	0.00	1.0e+00	KLC1 SNAP91 ZNF318
Medication: Ramipril	1.9	1	0	0.0	0.00	1.0e+00	FES
Birth weight of first child	1.9	2	1	2.2	0.00	1.0e+00	AS3MT FES
High blood pressure (siblings)	1.9	2	1	2.2	0.00	1.0e+00	FES SMG6
Medication for pain relief, constipation, heartburn	1.9	2	0	0.0	0.00	1.0e+00	PCNX SDCCAG8
Comparative height size at age 10	1.9	7	4	8.9	0.20	6.7e-01	AC103965.1 FES ITIH4-AS1 KLC1 MAPK3 NGEF PITPNM2
Overall health rating	1.9	4	0	0.0	0.53	4.7e-01	CPNE7 KLC1 LRRC48 SF3B1
Smoking status: Previous	1.9	1	0	0.0	0.00	1.0e+00	KIAA0319
Long-standing illness, disability or infirmity	1.9	1	0	0.0	0.00	1.0e+00	KLC1
Medication: Aspirin	1.9	1	1	2.2	0.00	1.0e+00	FES
Heart attack/myocardial infarction (self-reported)	1.9	1	1	2.2	0.00	1.0e+00	FES
Depressed Affect (Nagel 2018)	1.8	1	0	0.0	0.00	1.0e+00	CEP170
Depression (Nagel 2018)	1.8	1	0	0.0	0.00	1.0e+00	PCCB
Qualifications: None of the above	1.8	3	1	2.2	0.00	1.0e+00	ALMS1P ERCC8 PITPNM2
Mouth/teeth dental problems	1.8	1	0	0.0	0.00	1.0e+00	KLC1
Allergy	1.8	4	3	6.7	0.21	7.9e-01	FES PITPNM2 RERE SF3B1
Arm fat percentage (right)	1.8	7	3	6.7	0.05	9.2e-01	AS3MT C2orf47 CPNE7 FLJ10661 KLC1 MAPK3 SF3B1
Forced expiratory volume in 1-second (FEV1)	1.8	5	3	6.7	-0.77	1.2e-01	AC103965.1 CEP170 CHRNA5 FLJ10661 PLEKHO1
Breastfed as a baby	1.8	1	0	0.0	0.00	1.0e+00	PITPNM2
Qualifications: O levels/GCSEs or equivalent	1.8	2	0	0.0	0.00	1.0e+00	ALMS1P PITPNM2
Hypothyroidism/myxoedema (self-reported)	1.8	3	2	4.4	0.00	1.0e+00	FLJ10661 GIGYF1 RP11-981G7.6
Wheeze or whistling in the chest in last year	1.8	3	0	0.0	0.00	1.0e+00	ATG13 MAPK3 RERE
Arm fat percentage (left)	1.8	8	1	2.2	0.12	7.8e-01	AS3MT C2orf47 CPNE7 FLJ10661 KLC1 MAPK3 RERE SF3B1
Mood swings	1.8	1	0	0.0	0.00	1.0e+00	FLJ10661
Qualifications: nursing, teaching	1.8	3	0	0.0	0.00	1.0e+00	ALMS1P ERCC8 PITPNM2
Blood Platelet Count	1.7	12	7	15.6	-0.11	7.5e-01	AC011816.1 AC103965.1 AS3MT GMIP ITIH4-AS1 KIAA0319 NGEF PCCB PITPNM2 SF3B1 SMG6 SUGP2
Angina	1.7	1	1	2.2	0.00	1.0e+00	FES
Multivitamins +/- minerals	1.7	1	0	0.0	0.00	1.0e+00	BAI1
Medication: Cholesterol lowering	1.7	1	1	2.2	0.00	1.0e+00	FES
Forced expiratory volume in 1-second (FEV1), Best measure	1.7	4	2	4.4	-0.72	2.8e-01	AC103965.1 CEP170 CHRNA5 PLEKHO1
Mouth/teeth dental problems: Bleeding gums	1.7	1	0	0.0	0.00	1.0e+00	RP11-981G7.6
Medication: Amlodipine	1.7	1	1	2.2	0.00	1.0e+00	FES
Chronic bronchitis/emphysema (mother)	1.7	1	1	2.2	0.00	1.0e+00	CHRNA5
Angina (self-reported)	1.7	1	1	2.2	0.00	1.0e+00	FES
Medication: Aspirin	1.7	1	1	2.2	0.00	1.0e+00	FES
Average weekly champagne plus white wine intake	1.7	1	0	0.0	0.00	1.0e+00	RERE
Leg fat percentage (left)	1.7	3	1	2.2	0.00	1.0e+00	FLJ10661 MAPK3 RERE
Number of operations (self-reported)	1.7	1	0	0.0	0.00	1.0e+00	ERCC8
Height	1.6	14	11	24.4	-0.03	9.3e-01	AC103965.1 AS3MT CEP170 FES ITIH4-AS1 KLC1 LRRC48 MAPK3 MGAT3 NGEF PITPNM2 SDCCAG8 SUGP2 THOC7
Trunk fat percentage	1.6	5	3	6.7	0.24	6.9e-01	AC103965.1 CPNE7 MAPK3 RERE SF3B1
Age when periods started (menarche)	1.6	1	1	2.2	0.00	1.0e+00	MAPK3
Alcohol usually taken with meals	1.6	2	0	0.0	0.00	1.0e+00	ERCC8 FES
Medication: Simvastatin	1.6	1	1	2.2	0.00	1.0e+00	FES
Illnesses of siblings	1.6	1	1	2.2	0.00	1.0e+00	FES
Frequency of tiredness / lethargy in last 2 weeks	1.6	1	0	0.0	0.00	1.0e+00	KLC1
Standing height	1.6	11	4	8.9	-0.16	6.3e-01	AC103965.1 AS3MT CEP170 FLJ10661 ITIH4-AS1 KLC1 MAPK3 MGAT3 NGEF PITPNM2 SDCCAG8
Peak expiratory flow (PEF)	1.6	2	0	0.0	0.00	1.0e+00	FLJ10661 RP11-981G7.6
Body fat percentage	1.6	5	2	4.4	0.26	6.7e-01	AC103965.1 CPNE7 MAPK3 RERE SF3B1
Leg fat percentage (right)	1.6	3	1	2.2	0.00	1.0e+00	AC103965.1 MAPK3 RERE
Medication for cholesterol	1.6	1	0	0.0	0.00	1.0e+00	FES
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.6	3	1	2.2	0.00	1.0e+00	CHRNA5 MAPK3 PLEKHO1
Number of self-reported non-cancer illnesses	1.6	1	0	0.0	0.00	1.0e+00	LRRC48
Hearing aid user	1.6	1	0	0.0	0.00	1.0e+00	ERCC8
Blood Red Count	1.5	13	6	13.3	0.17	5.7e-01	AC103965.1 AS3MT C2orf47 GIGYF1 ITIH4-AS1 KLC1 LRRC48 MAPK3 PITPNM2 SF3B1 SMG6 SUGP2 VPS29
Respiratory disease	1.5	1	1	2.2	0.00	1.0e+00	RERE
Chronotype (morning person)	1.5	1	0	0.0	0.00	1.0e+00	SF3B1
Number of treatments/medications taken	1.5	1	0	0.0	0.00	1.0e+00	FES
Taking other prescription medications	1.5	1	0	0.0	0.00	1.0e+00	CPNE7
Medication: Levothyroxine sodium	1.5	2	1	2.2	0.00	1.0e+00	FLJ10661 GIGYF1
Hayfever/allergic rhinitis (self-reported)	1.5	1	0	0.0	0.00	1.0e+00	SF3B1
Alcohol intake versus 10 years previously	1.5	1	0	0.0	0.00	1.0e+00	MAPK3
Asthma	1.5	1	0	0.0	0.00	1.0e+00	RERE
Illnesses of mother	1.5	1	1	2.2	0.00	1.0e+00	FES
Alcohol intake frequency.	1.5	4	0	0.0	-0.60	4.0e-01	BAI1 CHRNA5 MAPK3 PITPNM2
Asthma (self-reported)	1.5	1	0	0.0	0.00	1.0e+00	RERE
Alzheimer’s Disease (including proxy)	1.4	1	0	0.0	0.00	1.0e+00	CYSTM1
Lupus	1.4	1	0	0.0	0.00	1.0e+00	FLJ10661
Blood White Count	1.4	10	9	20.0	0.41	2.4e-01	FES KLC1 LRRC48 MAPK3 MGAT3 NAGA PCCB RERE SMG6 THOC7
Hair Pigment	1.4	10	7	15.6	-0.51	1.3e-01	CPEB1 CPNE7 FAM53C FES GIGYF1 KLC1 PCNX PITPNM2 PLEKHO1 XPNPEP3
Hand grip strength (left)	1.4	4	0	0.0	0.34	6.6e-01	AS3MT FES MAPK3 SNAP91
Birth weight	1.4	2	1	2.2	0.00	1.0e+00	AS3MT FES
Forced expiratory volume in 1-second (FEV1), predicted	1.4	1	1	2.2	0.00	1.0e+00	AC103965.1
Average weekly beer plus cider intake	1.4	1	0	0.0	0.00	1.0e+00	FLJ10661
Heart disease (siblings)	1.4	1	0	0.0	0.00	1.0e+00	FES
Crohns Disease (2012)	1.3	1	0	0.0	0.00	1.0e+00	SF3B1
Blood Eosinophil Count	1.3	11	7	15.6	-0.16	6.3e-01	AC103965.1 GIGYF1 GMIP ITIH4-AS1 LRRC48 MAPK3 PITPNM2 RERE SF3B1 SUGP2 XPNPEP3
Lung FVC	1.3	6	3	6.7	-0.55	2.5e-01	CHRNA5 CPNE7 LRRC48 MAD1L1 PITPNM2 PLEKHO1
Relative age of first facial hair	1.3	1	0	0.0	0.00	1.0e+00	CEP170
Forced vital capacity (FVC)	1.3	4	1	2.2	-0.69	3.1e-01	AC103965.1 CEP170 CHRNA5 PLEKHO1
Average weekly red wine intake	1.3	1	0	0.0	0.00	1.0e+00	PITPNM2
Crohns Disease (2017)	1.2	2	0	0.0	0.00	1.0e+00	GIGYF1 SF3B1
Irritable Bowel Disease (IBD)	1.2	1	1	2.2	0.00	1.0e+00	GIGYF1
Hypothyroidism (self reported)	1.2	1	1	2.2	0.00	1.0e+00	GIGYF1
Relative age voice broke	1.2	1	0	0.0	0.00	1.0e+00	PCCB
Loneliness, isolation	1.2	1	0	0.0	0.00	1.0e+00	RERE
Pain experienced in last month	1.2	1	0	0.0	0.00	1.0e+00	LRRC48
Financial difficulties in last 2 years	1.1	1	0	0.0	0.00	1.0e+00	KLC1
Forced vital capacity (FVC), Best measure	1.1	3	1	2.2	0.00	1.0e+00	AC103965.1 CEP170 PLEKHO1

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Pancreas	7	0.44	2.6
GTEx	Prostate	4	0.49	2.6
GTEx	Small Intestine Terminal Ileum	3	0.68	2.6
GTEx	Brain Cerebellum	8	0.42	2.5
GTEx	Breast Mammary Tissue	13	0.68	2.5
GTEx	Cells EBV-transformed lymphocytes	8	0.58	2.5
GTEx	Colon Transverse	10	0.50	2.5
GTEx	Testis	23	0.75	2.5
GTEx	Brain Frontal Cortex BA9	2	0.22	2.4
GTEx	Brain Hippocampus	0	0.00	2.4
GTEx	Breast Mammary Tissue (Male)	6	0.53	2.4
GTEx	Cells Transformed fibroblasts	22	0.54	2.4
GTEx	Colon Sigmoid	8	0.56	2.4
GTEx	Esophagus Gastroesophageal Junction	7	0.50	2.4
GTEx	Esophagus Mucosa	13	0.40	2.4
GTEx	Heart Left Ventricle	8	0.54	2.4
GTEx	Liver	4	0.57	2.4
GTEx	Lung	13	0.47	2.4
GTEx	Ovary	3	0.34	2.4
GTEx	Pituitary	6	0.55	2.4
GTEx	Spleen	11	0.80	2.4
GTEx	Thyroid	20	0.52	2.4
GTEx	Whole Blood	10	0.52	2.4
ROSMAP	Brain Pre-frontal Cortex	17	0.40	2.4
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	9	0.57	2.4
The Cancer Genome Atlas	Esophageal Carcinoma	2	0.31	2.4
The Cancer Genome Atlas	Stomach Adenocarcinoma	4	0.25	2.4
GTEx	Adipose Subcutaneous	17	0.50	2.3
GTEx	Adipose Visceral Omentum	10	0.51	2.3
GTEx	Artery Aorta	14	0.49	2.3
GTEx	Artery Coronary	2	0.17	2.3
GTEx	Artery Tibial	17	0.47	2.3
GTEx	Brain Cortex	7	0.70	2.3
GTEx	Brain Nucleus accumbens basal ganglia	5	0.60	2.3
GTEx	Breast Mammary Tissue (Female)	10	0.64	2.3
GTEx	Esophagus Muscularis	19	0.61	2.3
GTEx	Heart Atrial Appendage	4	0.26	2.3
GTEx	Muscle Skeletal	8	0.28	2.3
GTEx	Nerve Tibial	19	0.45	2.3
GTEx	Skin Not Sun Exposed Suprapubic	10	0.42	2.3
GTEx	Skin Sun Exposed Lower leg	8	0.23	2.3
GTEx	Stomach	4	0.28	2.3
The Cancer Genome Atlas	Colon Adenocarcinoma	7	0.36	2.3
The Cancer Genome Atlas	Glioblastoma Multiforme	7	0.73	2.3
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	11	0.57	2.3
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	11	0.46	2.3
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	6	0.40	2.3
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	8	0.50	2.3
The Cancer Genome Atlas	Thyroid Carcinoma	23	0.47	2.3
GTEx	Adrenal Gland	7	0.49	2.2
GTEx	Brain Caudate basal ganglia	3	0.34	2.2
GTEx	Brain Cerebellar Hemisphere	2	0.14	2.2
GTEx	Brain Putamen basal ganglia	2	0.33	2.2
GTEx	Uterus	0	0.00	2.2
GTEx	Vagina	2	0.33	2.2
CommonMind	Brain Pre-frontal Cortex	14	0.27	2.2
The Cancer Genome Atlas	Breast Invasive Carcinoma	13	0.31	2.2
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	3	0.29	2.2
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	5	0.19	2.2
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	14	0.36	2.2
The Cancer Genome Atlas	Brain Lower Grade Glioma	12	0.29	2.2
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	3	0.28	2.2
The Cancer Genome Atlas	Lung Adenocarcinoma	8	0.29	2.2
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	7	0.56	2.2
The Cancer Genome Atlas	Prostate Adenocarcinoma	13	0.30	2.2
The Cancer Genome Atlas	Soft Tissue Sarcoma	3	0.30	2.2
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.20	2.2
The Cancer Genome Atlas	Testicular Germ Cell Tumors	8	0.66	2.2
GTEx	Brain Hypothalamus	3	0.53	2.1
METSIM	Adipose	11	0.24	2.1
NTR	Blood	5	0.21	2.1
YFS	Blood	14	0.31	2.1
The Cancer Genome Atlas	Rectum Adenocarcinoma	2	0.30	2.1
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.00	1.9